Compare Cipla with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs NOVARTIS - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA NOVARTIS CIPLA/
NOVARTIS
 
P/E (TTM) x 23.8 514.9 4.6% View Chart
P/BV x 2.4 28.9 8.4% View Chart
Dividend Yield % 0.7 1.5 43.2%  

Financials

 CIPLA   NOVARTIS
EQUITY SHARE DATA
    CIPLA
Mar-19
NOVARTIS
Mar-19
CIPLA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs678980 69.2%   
Low Rs484600 80.6%   
Sales per share (Unadj.) Rs198.2198.7 99.7%  
Earnings per share (Unadj.) Rs18.521.0 88.3%  
Cash flow per share (Unadj.) Rs35.022.3 157.2%  
Dividends per share (Unadj.) Rs3.0010.00 30.0%  
Dividend yield (eoy) %0.51.3 40.8%  
Book value per share (Unadj.) Rs186.3307.5 60.6%  
Shares outstanding (eoy) m805.7024.69 3,263.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.0 73.7%   
Avg P/E ratio x31.437.7 83.2%  
P/CF ratio (eoy) x16.635.5 46.8%  
Price / Book Value ratio x3.12.6 121.3%  
Dividend payout %16.247.7 34.0%   
Avg Mkt Cap Rs m468,03119,508 2,399.2%   
No. of employees `00022.60.6 3,897.4%   
Total wages/salary Rs m28,5651,171 2,439.2%   
Avg. sales/employee Rs Th7,053.18,445.4 83.5%   
Avg. wages/employee Rs Th1,261.52,015.7 62.6%   
Avg. net profit/employee Rs Th659.1891.0 74.0%   
INCOME DATA
Net Sales Rs m159,7104,907 3,254.9%  
Other income Rs m4,766783 609.0%   
Total revenues Rs m164,4755,689 2,890.9%   
Gross profit Rs m30,973123 25,222.4%  
Depreciation Rs m13,26332 41,707.9%   
Interest Rs m1,68416 10,593.1%   
Profit before tax Rs m20,791858 2,424.1%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,695340 1,675.1%   
Profit after tax Rs m14,924518 2,882.8%  
Gross profit margin %19.42.5 774.9%  
Effective tax rate %27.439.6 69.1%   
Net profit margin %9.310.6 88.6%  
BALANCE SHEET DATA
Current assets Rs m124,2668,055 1,542.8%   
Current liabilities Rs m37,7151,850 2,038.5%   
Net working cap to sales %54.2126.4 42.9%  
Current ratio x3.34.4 75.7%  
Inventory Days Days9145 201.3%  
Debtors Days Days9534 279.7%  
Net fixed assets Rs m105,190150 70,220.5%   
Share capital Rs m1,611123 1,305.8%   
"Free" reserves Rs m148,5117,469 1,988.5%   
Net worth Rs m150,1237,592 1,977.4%   
Long term debt Rs m38,3010-   
Total assets Rs m239,6339,824 2,439.2%  
Interest coverage x13.354.9 24.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.5 133.4%   
Return on assets %6.95.4 127.6%  
Return on equity %9.96.8 145.8%  
Return on capital %11.811.5 102.9%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41058 99,669.3%   
Fx outflow Rs m19,0411,326 1,435.7%   
Net fx Rs m38,368-1,269 -3,024.2%   
CASH FLOW
From Operations Rs m16,911-1,943 -870.5%  
From Investments Rs m-16,6872,742 -608.5%  
From Financial Activity Rs m-3,487-298 1,169.4%  
Net Cashflow Rs m-3,451501 -688.4%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 2.0 610.0%  
FIIs % 23.7 1.6 1,481.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.5 121.9%  
Shareholders   161,166 41,647 387.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT  SUVEN LIFESCIENCES  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 13, 2019 09:51 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS